Hospital
Methodist Hospital
Methodist Hospital was paid $10.65M by Medicaid between Jul 2019 and Dec 2024, across 175 billing codes. Its largest line is 99284, emergency room visit (serious) — 40% of everything it billed.
33Billing provider infoMETHODIST HOSPITAL
PHILADELPHIA, PA 19145
PHILADELPHIA, PA 19145
33aNPI1134297393assigned 12/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.65M
24GClaims152,559
24DCodes billed175
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#27 of 154
Median peer was paid$2.82M
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 817 | $21K | |
| 2020 | 23,522 | $1.36M | |
| 2021 | 54,193 | $4.24M | |
| 2022 | 18,118 | $1.57M | |
| 2023 | 26,657 | $2.03M | |
| 2024incomplete | 29,252 | $1.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 20,347 | 19,312 | $4.22M |
| G0378 | Hospital observation service, per hour | 16% | 2,063 | 1,191 | $1.73M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 7,006 | 6,702 | $1.55M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 5.0% | 3,433 | 3,403 | $535K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 2,224 | 2,047 | $470K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 2,101 | 1,962 | $318K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.0% | 977 | 624 | $210K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.3% | 3,403 | 3,353 | $139K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 230 | 218 | $115K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 265 | 254 | $97K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,248 | 716 | $79K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | <1% | 1,098 | 476 | $71K |
163 more codes
| 97602 | <1% | 571 | $70K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 426 | $57K |
| 77066 | Tomosynthesis, mammo | <1% | 273 | $49K |
| 76642 | <1% | 552 | $46K | |
| 97597 | <1% | 756 | $46K | |
| 76641 | <1% | 330 | $37K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,440 | $36K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 289 | $32K |
| 71250 | <1% | 299 | $32K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 471 | $30K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 403 | $28K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 671 | $26K |
| 77065 | Tomosynthesis, mammo | <1% | 199 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 295 | $25K |
| 76536 | <1% | 260 | $25K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,103 | $24K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 41 | $24K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 357 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,200 | $23K |
| 97598 | <1% | 221 | $22K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 150 | $22K |
| 76770 | <1% | 284 | $22K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,162 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,238 | $19K |
| 77080 | <1% | 206 | $19K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 167 | $18K |
| 72110 | <1% | 351 | $15K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,467 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,231 | $15K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 587 | $14K |
| 93970 | <1% | 110 | $14K | |
| 74183 | <1% | 15 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 330 | $11K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 201 | $10K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 16 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 97 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,337 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 411 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 95 | $8K |
| 10005 | <1% | 15 | $8K | |
| 94729 | <1% | 108 | $6K | |
| 73630 | <1% | 405 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,255 | $6K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 26 | $5K |
| 95886 | <1% | 58 | $5K | |
| 73030 | <1% | 215 | $5K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 244 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 172 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 105 | $5K |
| 84484 | <1% | 1,994 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,637 | $5K |
| 88342 | <1% | 132 | $5K | |
| 73564 | <1% | 213 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,480 | $4K |
| 72050 | <1% | 69 | $4K | |
| 80076 | <1% | 1,385 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 70 | $3K |
| 73610 | <1% | 157 | $3K | |
| 97161 | <1% | 114 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $2K |
| 97162 | <1% | 71 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 107 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 416 | $2K |
| 94726 | <1% | 44 | $2K | |
| 93971 | <1% | 27 | $2K | |
| 73130 | <1% | 190 | $2K | |
| 83880 | <1% | 289 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 418 | $2K |
| C1769 | Guide wire | <1% | 87 | $2K |
| 82803 | <1% | 291 | $2K | |
| A9270 | Non-covered item or service | <1% | 16,960 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 260 | $2K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 614 | $2K |
| 81001 | <1% | 923 | $2K | |
| 96417 | <1% | 17 | $2K | |
| 93975 | <1% | 25 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 260 | $1K |
| 73562 | <1% | 50 | $1K | |
| 83690 | <1% | 890 | $1K | |
| 76376 | <1% | 44 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,313 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 605 | $1K |
| 85730 | <1% | 494 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 240 | $1K |
| 73502 | <1% | 44 | $1K | |
| 83605 | <1% | 571 | $1K | |
| 85027 | <1% | 225 | $1K | |
| 93922 | <1% | 14 | $970.37 | |
| 90715 | <1% | 106 | $840.94 | |
| 73110 | <1% | 68 | $837.03 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 63 | $808.46 |
| 83735 | <1% | 667 | $775.05 | |
| 85610 | <1% | 582 | $745.69 | |
| 0001A | <1% | 15 | $679.02 | |
| 87077 | <1% | 204 | $652.43 | |
| 80320 | <1% | 121 | $646.82 | |
| 85379 | <1% | 258 | $637.18 | |
| 87040 | <1% | 147 | $560.20 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 552 | $555.81 |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 140 | $546.81 |
| 86900 | <1% | 226 | $482.59 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 964 | $433.90 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 152 | $404.67 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 30 | $385.30 |
| 86850 | <1% | 149 | $334.07 | |
| 96376 | <1% | 241 | $303.30 | |
| 94060 | <1% | 14 | $299.80 | |
| 72100 | <1% | 38 | $299.45 | |
| 81003 | <1% | 359 | $299.37 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,247 | $276.13 |
| 84702 | <1% | 56 | $262.72 | |
| 86901 | <1% | 192 | $230.40 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 21 | $193.18 |
| 87186 | <1% | 89 | $168.36 | |
| 82550 | <1% | 82 | $153.62 | |
| 73080 | <1% | 14 | $150.20 | |
| 80329 | <1% | 15 | $86.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,061 | $84.60 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 22 | $79.18 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,118 | $75.90 |
| J3490 | Unclassified drugs | <1% | 3,570 | $74.13 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,435 | $67.06 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,531 | $66.95 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 647 | $65.10 |
| 87205 | <1% | 30 | $61.19 | |
| 87070 | <1% | 12 | $47.94 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,058 | $47.36 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 700 | $44.42 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15 | $39.41 |
| 86140 | <1% | 36 | $30.87 | |
| 84100 | <1% | 70 | $27.19 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,307 | $24.69 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 577 | $16.97 |
| 85652 | <1% | 12 | $15.05 | |
| 83540 | <1% | 15 | $12.05 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 949 | $10.75 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 570 | $10.33 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 398 | $7.14 |
| 83550 | <1% | 13 | $7.13 | |
| J1815 | Injection, insulin, per 5 units | <1% | 743 | $5.62 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $4.70 |
| 88300 | 0% | 15 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 323 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 214 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 508 | $0.00 |
| 00000 | 0% | 169 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 13 | $0.00 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 30 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 54 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 39 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 24 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 128 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 108 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 352 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 194 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 767 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 274 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 15 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 45 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 52 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 66 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 30 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 61 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUBARSKY, NEIL (SENIOR VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Thomas Jefferson University Hospitals INC | Philadelphia, PA | $40.28M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.